Synlogic (NASDAQ:SYBX) has been given a $20.00 price target by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, May 11th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 100.60% from the stock’s current price.
Other equities research analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Synlogic from a “strong sell” rating to a “sell” rating in a research report on Friday, April 27th. Piper Jaffray reiterated a “buy” rating and set a $15.00 price target on shares of Synlogic in a research report on Monday, April 9th. Finally, Zacks Investment Research cut shares of Synlogic from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Synlogic currently has an average rating of “Hold” and an average price target of $20.00.
Shares of SYBX opened at $9.97 on Friday. Synlogic has a 1-year low of $10.16 and a 1-year high of $10.50. The stock has a market cap of $199.44 million, a price-to-earnings ratio of -1.70 and a beta of 2.06.
Several hedge funds have recently made changes to their positions in SYBX. Spark Investment Management LLC acquired a new position in shares of Synlogic in the fourth quarter valued at approximately $105,000. DRW Securities LLC acquired a new position in shares of Synlogic in the first quarter valued at approximately $178,000. Element Capital Management LLC acquired a new position in shares of Synlogic in the first quarter valued at approximately $182,000. Deutsche Bank AG grew its holdings in shares of Synlogic by 204.0% in the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 13,200 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Synlogic in the fourth quarter valued at approximately $191,000. Hedge funds and other institutional investors own 56.20% of the company’s stock.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.